Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial  Veronica Mulenga, MSc, Victor Musiime, PhD, Adeodata Kekitiinwa, MMed, Adrian D Cook, MSc, George Abongomera, MSc, Julia Kenny, BMBCh, Chisala Chabala, MMed, Grace Mirembe, MMed, Alice Asiimwe, MSc, Ellen Owen-Powell, MRes, Prof David Burger, PhD, Helen McIlleron, PhD, Prof Nigel Klein, PhD, Prof Chifumbe Chintu, FRCPC, Margaret J Thomason, PhD, Cissy Kityo, MSc, Prof A Sarah Walker, PhD, Prof Diana M Gibb, MD  The Lancet Infectious Diseases  Volume 16, Issue 2, Pages 169-179 (February 2016) DOI: 10.1016/S1473-3099(15)00319-9 Copyright © 2016 Walker et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile ART=antiretroviral treatment. *Includes one not seen after randomisation. †One participant started stavudine and substituted zidovudine at 12 weeks, two started abacavir and did not change (both prescribing errors). ‡Two started zidovudine and did not change (one prescribing error and one child changed regimen to match twin sibling). The Lancet Infectious Diseases 2016 16, 169-179DOI: (10.1016/S1473-3099(15)00319-9) Copyright © 2016 Walker et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Primary endpoint (clinical adverse event grade 2 or higher, confirmed laboratory grade 3 adverse event, or any laboratory grade 4 adverse event; A) and grade 3 or 4 primary endpoint (B) ART=antiretroviral treatment. The Lancet Infectious Diseases 2016 16, 169-179DOI: (10.1016/S1473-3099(15)00319-9) Copyright © 2016 Walker et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Viral suppression in patients with less than 400 copies per mL (A) and viral less than 100 copies per mL (B) Data are the absolute (95% CI) between-group differences in overall suppression. ART=antiretroviral treatment. S=stavudine. Z=zidovudine. A=abacavir. The Lancet Infectious Diseases 2016 16, 169-179DOI: (10.1016/S1473-3099(15)00319-9) Copyright © 2016 Walker et al. Open Access article distributed under the terms of CC BY Terms and Conditions